BRIGHTPATH BIOTHERAPEUTICS
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.
BRIGHTPATH BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2003-05-08
Address:
Kurume, Fukuoka, Japan
Country:
Japan
Website Url:
http://www.brightpathbio.com
Total Employee:
1+
Status:
Active
Contact:
81 942 38 6550
Total Funding:
11.54 M USD
Technology used in webpage:
NTT PC Communications
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-11-21 | Advanced Immunotherapy | Advanced Immunotherapy acquired by BrightPath Biotherapeutics | N/A |
Investors List
Nippon Venture Capital
Nippon Venture Capital investment in Venture Round - BrightPath Biotherapeutics
KSP
KSP investment in Venture Round - BrightPath Biotherapeutics
Sansei Capital Investment
Sansei Capital Investment investment in Venture Round - BrightPath Biotherapeutics
MBLVC
MBLVC investment in Venture Round - BrightPath Biotherapeutics
Ibis Capital Partners
Ibis Capital Partners investment in Venture Round - BrightPath Biotherapeutics
Innovation Engine
Innovation Engine investment in Venture Round - BrightPath Biotherapeutics
DBJ Capital
DBJ Capital investment in Seed Round - BrightPath Biotherapeutics
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Funding Round - BrightPath Biotherapeutics
Official Site Inspections
http://www.brightpathbio.com Semrush global rank: 196.02 K Semrush visits lastest month: 393.43 K
- Host name: 150.60.196.79
- IP address: 150.60.196.79
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "BrightPath Biotherapeutics"
Company Overview & History - brightpathbio.com
May 8, 2003 Company Name: BrightPath Biotherapeutics Co., Ltd. Location: Corporate Headquarters: Kojimachi Central Building 7F, 2-2-4 Kojimachi, Chiyoda-ku, Tokyo MAP …See details»
ブライトパス・バイオ株式会社
ブライトパス・バイオはがん治療の革新とフロンティア拡大をもたらしつつある「がん免疫療法」の開発を行う創薬ベンチャーです。後期臨床試験段階から創薬探索段階までの様々な医薬品形態のパイプラインを持ち、グローバルで開発 …See details»
Corporate Identity｜Company Profile｜BrightPath …
Company Logo. The horizontal line at the end of the logo represents a leap into new fields, as, with the new "BrightPath" as the starting point, the company's mission is to generate and tie together various new ideas, so as to create a …See details»
BrightPath Biotherapeutics Co., Ltd.
Science iPS–NKT. iPS-NKT: induced pluripotent stem cells (iPSC) derived natural killer T-cell (NKT cell) therapy iPS-NKT is a novel allogeneic cell therapy agent that uses NKT cells …See details»
BRIGHTPATH BIOTHERAPEUTICS CO., LTD. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BRIGHTPATH BIOTHERAPEUTICS CO., LTD. of CHIYODA-KU, TOKYO. Get the latest business insights …See details»
BrightPath Biotherapeutics - Crunchbase Company Profile & Funding
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine …See details»
BrightPath Biotherapeutics Company Description - Stock Analysis
Mar 19, 2025 BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine …See details»
BrightPath Biotherapeutics - Overview, News & Similar ... - ZoomInfo
Www.brightpathbio.com. Revenue $18.3 Million. Industry Chemicals, Petrochemicals, Glass & Gases Manufacturing . Recent News & Media. No recent news or media. Overview ; Org Chart …See details»
BrightPath Biotherapeutics - Craft
Oct 29, 2024 BrightPath Biotherapeutics is a company that specializes in cancer immunotherapy. It develops a cancer peptide vaccine GRN-1201, immunomodulatory …See details»
Bio Venture Directory BrightPath Biotherapeutics Co., Ltd.
Highlights (GRN-1201) 2015 Start of phase I for malignant melanoma in the U.S. 2017 Start of phase II in combination with immune checkpoint inhibitor for NSCLC in the U.S.See details»
BrightPath Biotherapeutics - VentureRadar
Website: https://www.brightpathbio.com/ Specializes in innovative cancer immunotherapy using iPS-NKT technology to mass-produce natural killer T cells for allogeneic ...See details»
BrightPath Biotherapeutics CEO and Key Executive Team
BrightPath Biotherapeutics's Director and Professor, Kurume University Research Center for Innovative Cancer Therapy is Akira Yamada. Other executives include Kenichi Nagai, CEO; …See details»
BrightPath Biotherapeutics - Products, Competitors, Financials ...
Oct 22, 2015 brightpathbio.com. Overview & Products; Financials; Alternatives & Competitors; Founded Year 2003. Stage IPO | IPO. Date of IPO 10/22/2015. ... More specifically, these …See details»
Shinshu University and BrightPath Conclude Joint R&D Agreement …
Sep 12, 2019 Tokyo, August 19, 2019 — National University Corporation Shinshu University and BrightPath Biotherapeutics Co., Ltd., an immuno-oncology company, announced the …See details»
BrightPath Bio and Cellistic Announce Process Development and ...
Dec 13, 2024 Tokyo, Japan and Mont-Saint-Guibert, Belgium, – December 13th, 2024 BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell …See details»
Management Team｜Company Profile｜BrightPath …
About 'Management Team' in BrightPath Biotherapeutics Co., Ltd. Director. Akira Yamada,Ph.D. Director and Professor, Kurume University Research Center for Innovative Cancer Therapy …See details»
BrightPath Biotherapeutics and Artisan Bio Announce Research …
May 2, 2023 /PRNewswire/ -- BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), a clinical stage biotechnology company focused on the development of cell therapies derived...See details»
BrightPath, Artisan Bio sign agreement to expedite cell therapies
May 3, 2023 BrightPath Biotherapeutics CEO Kenichi Nagai stated: “This collaboration with Artisan provides us with the potential to create highly engineered allogeneic iNKT cellular …See details»
Investor Relations｜BrightPath Biotherapeutics Co., Ltd.
Nov 14, 2023 About 'Investor Relations' in BrightPath Biotherapeutics Co., Ltd. 2024.11.8 Financial Results for the Six Months ended September 30, 2024 [Japanese GAAP] (non …See details»
Pipeline｜BrightPath Biotherapeutics Co., Ltd.
About 'Pipeline' in BrightPath Biotherapeutics Co., Ltd. *This table can be scrolled horizontallySee details»